Log in to search using one of your social media accounts:

 

NOVOLOG (Insulin Aspart) Injection, Solution
Updated Date: Mar 23, 2017 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - March 23, 2017 Category: Drugs & Pharmacology Source Type: news

NovoLog Mix 70/30 (Insulin Aspart Protamine and Insulin Aspart (rDNA origin)) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 2, 2017 Category: Drugs & Pharmacology Source Type: news

NOVOLOG MIX 70/30 (Insulin Aspart) Injection, Suspension [A-S Medication Solutions]
Updated Date: Dec 2, 2016 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - December 2, 2016 Category: Drugs & Pharmacology Source Type: news

NovoLog Mix 50/50 (50% Insulin Aspart Protamine Suspension and 50% Insulin Aspart Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news

NovoLog (Insulin Aspart [rDNA origin] Inj) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 10, 2016 Category: Drugs & Pharmacology Source Type: news

Companion Medical wins FDA nod for InPen insulin pen
Companion Medical said today it won FDA 510(k) approval for its wireless-enabled InPen insulin pen and mobile application. The InPen is designed to connect to smartphones via bluetooth and send data back, including insulin dosage and timing, the company said. The app allows patients to track and calculate doses, and set alarms for future doses. “FDA clearance of the InPen and mobile app represents a significant advancement in diabetes care. The product combines the benefits of sophisticated insulin pumps with the simplicity and affordability of pens and syringes, providing patients, physicians, and caregivers increas...
Source: Mass Device - July 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: 510(k) Diabetes Food & Drug Administration (FDA) Regulatory/Compliance Companion Medical Source Type: news

Mannkind taps medtech reps after Sanofi deal fails
Mannkind chief commercial officer Michael Castagna is trying to resuscitate the inhaled insulin maker after its co-marketing agreement with Sanofi (NYSE:SNY) was cancelled at the beginning of the year due to disappointing sales. He’s fielding a team of about 70 people to sell the company’s Afrezza insulin inhaler, with about ⅓ coming from the medical device industry. “We are looking to build a high energy nimble company that reflects the speed of the medical device industry, articulation of the science from biotech and a relentless focus on helping patients suffering from diabetes,” Castagna told ...
Source: Mass Device - June 28, 2016 Category: Medical Equipment Authors: Varun Saxena Tags: Business/Financial News Diabetes Drug-Device Combinations Mannkind Corp. Sanofi-Aventis newtag Source Type: news

NOVOLOG (Insulin Aspart) Injection, Solution [TYA Pharmaceuticals]
Updated Date: Sep 29, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - September 29, 2014 Category: Drugs & Pharmacology Source Type: news

Novo Nordisk receives U.S. FDA clearance for the insulin injection device NovoPen Echo(R)
First insulin injection device to combine half-unit dosing with a memory function to help patients better manage their diabetes PLAINSBORO, N.J., Aug. 21, 2013 -- (Healthcare Sales & Marketing Network) -- Novo Nordisk, a world leader in diabetes care, ... Biopharmaceuticals, Devices, Drug Delivery, FDANovo Nordisk, NovoPen Echo, NovoLog, insulin, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 21, 2013 Category: Pharmaceuticals Source Type: news